Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma

Shannon K. Quirk, Anna K. Shure, Devendra K. Agrawal

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152), was approved by the Food and Drug Administration in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies and specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.

Original languageEnglish
Pages (from-to)412-424
Number of pages13
JournalTranslational Research
Volume166
Issue number5
DOIs
StatePublished - Nov 1 2015

Fingerprint

T-cells
Melanoma
T-Lymphocytes
Antigens
Antibodies
CTLA-4 Antigen
Biomarkers
Therapeutics
United States Food and Drug Administration
Colitis
Immunotherapy
Nervous System
ipilimumab
Diarrhea
Kidney

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Biochemistry, medical
  • Public Health, Environmental and Occupational Health

Cite this

Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. / Quirk, Shannon K.; Shure, Anna K.; Agrawal, Devendra K.

In: Translational Research, Vol. 166, No. 5, 01.11.2015, p. 412-424.

Research output: Contribution to journalReview article

@article{6bafb060a05f4a4b8192b6ec523cb910,
title = "Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma",
abstract = "Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152), was approved by the Food and Drug Administration in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies and specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.",
author = "Quirk, {Shannon K.} and Shure, {Anna K.} and Agrawal, {Devendra K.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.trsl.2015.06.005",
language = "English",
volume = "166",
pages = "412--424",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma

AU - Quirk, Shannon K.

AU - Shure, Anna K.

AU - Agrawal, Devendra K.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152), was approved by the Food and Drug Administration in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies and specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.

AB - Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152), was approved by the Food and Drug Administration in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies and specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84944281519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944281519&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2015.06.005

DO - 10.1016/j.trsl.2015.06.005

M3 - Review article

VL - 166

SP - 412

EP - 424

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 5

ER -